
  
    
      
        
        Adverse_JJ side_NN effects_NNS ,_, viral_JJ resistance_NN ,_, and_CC the_DT high_JJ cost_NN of_IN antiretroviral_NN therapies_NNS
        remain_VBP obstacles_NNS in_IN the_DT way_NN of_IN turning_VBG HIV_NNP /_NN AIDS_NNP into_IN a_DT manageable_JJ chronic_JJ disease_NN ._.
        Structured_NNP treatment_NN interruptions_NNS (_( STIs_NNP )_) in_IN individuals_NNS who_WP have_VBP good_JJ viral_JJ control_NN on_IN
        therapy_NN have_VBP been_VBN proposed_VBN as_IN a_DT strategy_NN for_IN overcoming_VBG these_DT obstacles_NNS ._. The_DT initial_JJ hope_NN
        that_IN STIs_NNP would_MD help_VB patients_NNS achieve_VB greater_JJR viral_JJ control_NN has_VBZ so_RB far_RB not_RB been_VBN supported_VBN
        by_IN data_NNS from_IN clinical_JJ trials_NNS ,_, but_CC interrupting_VBG treatment_NN has_VBZ also_RB been_VBN proposed_VBN as_IN a_DT
        strategy_NN to_TO reduce_VB the_DT cost_NN of_IN long-term_JJ therapy_NN and_CC drug-associated_JJ toxicity_NN ._.
        Luis_NNP Montaner_NNP and_CC colleagues_NNS now_RB report_VBP results_NNS from_IN a_DT randomized_JJ trial_NN of_IN 42_CD
        participants_NNS (_( 75_CD %_NN on_IN their_PRP$ second_JJ to_TO fourth_JJ regimen_NN ,_, 66_CD %_NN on_IN regimens_NNS containing_VBG
        non-nucleoside_JJ reverse-transcriptase_JJ inhibitors_NNS )_) who_WP received_VBD either_CC continuous_JJ therapy_NN for_IN
        40_CD weeks_NNS or_CC three_CD successive_JJ treatment_NN interruptions_NNS of_IN two_CD ,_, four_CD ,_, and_CC six_CD weeks_NNS ,_, followed_VBN
        by_IN a_DT final_JJ open-ended_JJ interruption_NN for_IN both_DT groups_NNS ._.
        The_DT study_NN was_VBD designed_VBN to_TO be_VB able_JJ to_TO detect_VB a_DT difference_NN of_IN four_CD weeks_NNS or_CC greater_JJR
        between_IN the_DT two_CD groups_NNS for_IN the_DT time_NN to_TO viral_JJ rebound_NN during_IN the_DT open-ended_JJ interruption—the_NN
        primary_JJ outcome_NN ._. No_DT difference_NN between_IN the_DT two_CD groups_NNS was_VBD seen_VBN (_( median_JJ time_NN for_IN the_DT group_NN
        on_IN continuous_JJ treatment_NN was_VBD four_CD weeks_NNS ,_, and_CC for_IN the_DT STI_NNP group_NN was_VBD five_CD weeks_NNS )_) ._.
        Secondary_JJ outcomes_NNS included_VBD serious_JJ adverse_JJ events_NNS (_( disease_NN progression_NN ,_, acute_JJ
        retroviral_NN syndrome_NN ,_, therapy_NN failure_NN ,_, or_CC opportunistic_JJ infections_NNS at_IN any_DT point_NN in_IN the_DT
        study_NN )_) ,_, changes_NNS in_IN CD_NNP 4_CD count_NN on_IN therapy_NN ,_, immune_JJ reconstitution_NN changes_NNS (_( CD_NNP 4_CD recall_VB
        responses_NNS and_CC CD_NNP 4_CD naïve_NN /_NN memory_NN T_NN cell_NN distribution_NN )_) ,_, and_CC detection_NN of_IN viral_JJ mutations_NNS There_RB
        were_VBD no_DT study-related_JJ serious_JJ adverse_JJ events_NNS in_IN either_DT group_NN and_CC no_DT increase_NN of_IN therapy_NN
        failure_NN in_IN the_DT STI_NNP arm_NN ._. CD_NNP 4_CD counts_VBZ fluctuated_VBN between_IN the_DT start_NN and_CC end_VB of_IN each_DT monitored_VBN
        treatment_NN interruption_NN ,_, but_CC levels_NNS recovered_VBD after_IN resuppression_NN of_IN virus_NN ,_, with_IN retention_NN
        of_IN recall_NN responses_NNS throughout_IN ._. Viral_NNP resistance_NN was_VBD detected_VBN in_IN both_DT groups_NNS (_( in_IN seven_CD of_IN
        21_CD patients_NNS in_IN the_DT continuous_JJ treatment_NN group_NN and_CC ten_CD of_IN 21_CD patients_NNS in_IN the_DT STI_NNP group_NN )_) ,_, but_CC
        it_PRP was_VBD more_RBR commonly_RB detected_VBD (_( 50_CD %_NN versus_CC 18_CD %_NN )_) in_IN the_DT STI_NNP group_NN during_IN the_DT open-ended_JJ final_JJ
        interruption_NN ,_, even_RB though_IN all_DT subjects_NNS suppressed_VBD virus_NN upon_IN reinitiating_VBG the_DT same_JJ
        therapy_NN ._.
        Possible_JJ risks_NNS and_CC benefits_NNS of_IN STIs_NNP remain_VB controversial_JJ ,_, but_CC data_NNS from_IN this_DT and_CC other_JJ
        published_VBN trials_NNS do_VBP not_RB support_VB short-term_JJ clinical_JJ benefits_NNS of_IN treatment_NN interruptions_NNS ._.
        However_RB ,_, because_IN they_PRP do_VBP not_RB see_VB increased_VBN therapy_NN failure_NN and_CC find_VB preservation_NN of_IN immune_JJ
        function_NN in_IN the_DT STI_NNP group_NN ,_, the_DT authors_NNS conclude_VBP that_RB ,_, in_IN light_NN of_IN the_DT possibility_NN of_IN
        reducing_VBG costs_NNS and_CC drug-related_JJ toxicity_NN ,_, additional_JJ trials_NNS of_IN STIs_NNP are_VBP warranted_VBN ._.
        Particularly_RB important_JJ in_IN the_DT debate_NN over_IN the_DT safety_NN of_IN STIs_NNP is_VBZ whether_IN the_DT detection_NN of_IN
        resistant_JJ mutants_NNS should_MD be_VB of_IN concern_NN ._. The_DT authors_NNS point_VBP out_IN that_IN all_DT participants_NNS were_VBD
        able_JJ to_TO resuppress_NNS the_DT mutant_JJ virus_NN when_WRB they_PRP resumed_VBD their_PRP$ previous_JJ drug_NN regimens_NNS but_CC
        state_NN that_IN it_PRP remains_VBZ undetermined_JJ to_TO what_WP extent_NN resistant_JJ mutations_NNS are_VBP a_DT signal_NN for_IN
        future_JJ therapy_NN failure_NN ._. Moreover_RB ,_, viral_JJ replication_NN and_CC rebound—which_NN eventually_RB occurred_VBD
        in_IN all_DT participants—is_NNS seen_VBN by_IN some_DT researchers_NNS as_RB inherently_RB detrimental_JJ ,_, and_CC these_DT
        experts_NNS argue_VBP that_IN treatment_NN interruptions_NNS are_VBP unsafe_JJ and_CC their_PRP$ use_NN should_MD be_VB
        discontinued_VBN ._.
        What_WP seems_VBZ clear_JJ is_VBZ that_IN STIs_NNP have_VBP no_DT place_NN outside_IN controlled_VBN clinical_JJ trials_NNS and_CC that_IN
        questions_NNS regarding_VBG long-term_JJ safety_NN remain_VB unanswered_JJ ._. At_IN least_JJS a_DT dozen_NN additional_JJ trials_NNS
        that_WDT examine_VBP STIs_NNP are_VBP currently_RB recruiting_VBG patients_NNS and_CC will_MD help_VB answer_VB these_DT
        questions_NNS ._.
      
    
  
